<DOC>
	<DOCNO>NCT01946373</DOCNO>
	<brief_summary>The purpose study learn dendritic cell vaccine increase effect tumor infiltrate lymphocyte give chemotherapy interleukin-2 patient melanoma .</brief_summary>
	<brief_title>T Cell Transfer With Without Dendritic Cell Vaccination Patients With Melanoma</brief_title>
	<detailed_description>The MAT02 clinical trial phase 1 clinical trial objective ass safety , feasibility immunological efficacy combine application two immunological treatment modality patient metastatic melanoma : 1 . Cohort A : After non-myeloablative conditioning regimen , 5 patient receive one bulk infusion T cell . T cell expand ex vivo autologous tumor infiltrate lymphocyte ( TIL ) . In vivo persistence infuse cell support administration IL-2 , T cell survival factor . 2 . Cohort B : This adoptive cell transfer ( ACT ) step additional 5 patient follow vaccination autologous , vitro-generated , dendritic cell ( DC ) , load autologous tumor lysate synthetically produce peptide derived tumor associate antigen NY-ESO 1 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients measurable ( direct body surface xray and/or CT ) malignant melanoma , advance , inoperable stage III ( advanced regional lymph node metastasis , 5 intransit metastasis , N2 ) stage IV ( distant metastasis , M1 ) accord AJCC classification confirm histology/cytology appropriate radiological investigation . Patients palpable resectable lesion locate skin lymph node lesion accessible ( core ) biopsy . The lesion confirm melanoma fine needle biopsy . Disease progression patient exhaust approve therapeutic option . Ambulatory performance status ( ECOG 0 , 1 , 2 ) . Age 1874 life expectancy great 3 month . Patients must evaluate image study ( MRI/CT/US/PETCT ) establish metastasis/advanced disease period 30 day prior initiation trial . Any criteria met . Significant history current evidence cardiovascular disease ( e.g . uncontrolled congestive heart failure hypertension , unstable coronary artery disease serious arrhythmia ) major respiratory disease . In questionable case , stress test perform . Recipients major organ allograft . Autoimmune diseases , limited , inflammatory bowel disease multiple sclerosis . Vitiligo exclusion criterion . Other serious chronic disease . Other serious illness , e.g . active infection require antibiotic , bleed disorder . Has prior systemic cancer therapy within past four week time start lymphodepletion regimen . Patients diagnose prior malignancy ( except adequately treat basal cell carcinoma skin situ carcinoma skin situ carcinoma cervix , surgically cure ) . Patients second advanced malignancy concurrently . CNS metastasis . ( Note : Patients brain metastasis completely resect least one month prior registration undergone gamma knife treatment evidence recurrence CT neurologically stable , exclude ) . Organic brain syndrome significant psychiatric disorder would preclude participation full protocol followup . Immunodeficiency , previous splenectomy radiation therapy spleen . Screening laboratory value : ) Inadequate hematologic function define : ) White blood count ( WBC ) &lt; 3.0 x 109/l ii ) Platelet count &lt; 100x109/l iii ) Hemoglobin level &lt; 100 g/l b ) Inadequate hepatic function define either : ) Total bilirubin level &gt; 1.5 time upper limit normal ( ULN ) ii ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; 3 time ULN ( relate liver metastases &gt; 5 time ULN ) c ) Inadequate renal function define serum creatinine &gt; 1.5 time ULN Infectious disease transmit via contact blood , HIV , Hepatitis B C. Women pregnant nursing exclude potentially dangerous effect preparative chemotherapy fetus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Dendritic cell vaccination</keyword>
	<keyword>Lymphodepletion</keyword>
	<keyword>Adoptive cell transfer</keyword>
	<keyword>T cell</keyword>
	<keyword>Tumor infiltrate lymphocyte</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>IL-2</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Monocytes</keyword>
	<keyword>Autologous</keyword>
	<keyword>NY-ESO-1</keyword>
</DOC>